Head to Head Review: Evogene (EVGN) vs. Its Competitors

Evogene (NASDAQ:EVGN) is one of 846 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Evogene to similar businesses based on the strength of its earnings, dividends, institutional ownership, risk, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Evogene and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Evogene	$3.85 million	-$8.48 million	-0.42
Evogene Competitors	$729.47 million	$11.46 million	-14.89

Evogene’s competitors have higher revenue and earnings than Evogene. Evogene is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Evogene has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Evogene’s competitors have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Profitability

This table compares Evogene and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Evogene Competitors	-12,285.98%	-196.04%	-30.61%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Evogene and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1	0	0	0	1.00
Evogene Competitors	9904	15276	45614	1595	2.54

As a group, “Biotechnology” companies have a potential upside of 99.30%. Given Evogene’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Evogene has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

10.4% of Evogene shares are held by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are held by institutional investors. 7.4% of Evogene shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Evogene competitors beat Evogene on 9 of the 13 factors compared.

Evogene Company Profile

Evogene Ltd. (NASDAQ: EVGN) is an Israel-based computational biology company that develops technologies and products designed to improve human health, agriculture and sustainability. The company uses artificial intelligence, machine learning and biological data analysis through its Computational Predictive Biology platform to identify and develop solutions based on biological mechanisms. Evogene has built a portfolio of subsidiaries and business units focused on areas including agricultural biologicals, crop protection, microbiome-based therapeutics and medical cannabis.